EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Contrast-enhanced ultrasound with VEGFR2-targeted microbubbles for monitoring combined anti-PD-L1/anti-CTLA-4 immunotherapy effects in a murine melanoma model with immunohistochemical validation

Felix L Herr iD, Melissa J Antons, Larissa V Blume, Heidrun Hirner-Eppeneder, Sandra Kloiber-Langhorst, Amra Cimic, Jennifer Stueckl, Isabelle Tardy, Tanja Burkard, Jens Ricke, Wolfgang G Kunz, Dirk-Andre Clevert und 2 weitere

PLOS One · 2025

DOI: 10.1371/journal.pone.0326675 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Felix L Herr und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, LMU University Hospital Munich, Munich, Germany. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor Receptor-2, CTLA-4 Antigen, Microbubbles, Immunotherapy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors (ICIs) have emerged as a highly effective treatment option for patients with metastatic melanoma. As not all patients respond to ICI immunotherapy, imaging biomarkers are required to accurately monitor early response to therapy. Therefore, the aim of this study was to evaluate contrast-enhanced ultrasound (CEUS) with VEGFR2-targeted microbubbles for monitoring the effects of combined anti-PD-L1/anti-CTLA-4 immunotherapy in a murine melanoma model.

Methods

Murine melanoma allografts (B16-F10) were implanted subcutaneously in n = 10 therapy and n = 10 control female C57BL/6 mice. CEUS with VEGFR2-targeted microbubbles was performed on day 7 and 12. The therapy group received 3 intraperitoneal injections on days 7, 9, 11 of combined anti-PD-L1/anti-CTLA-4 immunotherapy, the control group received a placebo. CEUS assessed tumour perfusion during an early vascular phase (wash-in area under the curve = WiAUC) and VEGFR2-specific binding during a late molecular phase (signal intensity at 8 minutes (SI 8min ) and 10 minutes (SI 10min )). For pathophysiological validation immunohistochemistry was performed.

Results

At follow-up, the CEUS perfusion parameter WiAUC demonstrated a significantly higher decrease in the therapy than in the control group (p = 0.021). At follow-up, the signal enhancement in the late phase was significantly lower in the therapy than in the control group (SI 8min p = 0.003; SI 10min p = 0.002). Immunohistochemistry revealed significantly more apoptotic tumour cells (p = 0.001), more tumour infiltrating lymphocytes (p = 0.049), lower tumour cell proliferation (p = 0.001), lower microvascular density (p = 0.003) and lower VEGFR2 expression (p = 0.003) in the therapy than in the control group.

Conclusions

CEUS with VEGFR2-targeted microbubbles allowed for monitoring early treatment effects of a combined anti-PD-L1/anti-CTLA-4 immunotherapy on melanoma allografts with significantly lower tumour perfusion and significantly lower binding of VEGFR2-targeted microbubbles in the therapy than in the control group.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vascular Endothelial Growth Factor Receptor-2CTLA-4 AntigenMicrobubblesImmunotherapyImmune Checkpoint InhibitorsMelanoma, ExperimentalB7-H1 AntigenAnimalsMiceFemaleUltrasonographyContrast MediaMice, Inbred C57BLDisease Models, AnimalCell Line, TumorImmunohistochemistry

Substanzen

Vascular Endothelial Growth Factor Receptor-2CTLA-4 AntigenContrast MediaImmune Checkpoint InhibitorsB7-H1 AntigenKdr protein, mouseCd274 protein, mouseCtla4 protein, mouse

Autor:innen und Institutionen

  • Department of Radiology, LMU University Hospital Munich, Munich, Germany.
  • Bracco Suisse South Australia, Geneva, Switzerland.

ORCID-Profile: Felix L Herr

Zitieren

APA

Herr, F. L., Antons, M. J., Blume, L. V., Hirner-Eppeneder, H., Kloiber-Langhorst, S., Cimic, A., Stueckl, J., Tardy, I., Burkard, T., Ricke, J., Kunz, W. G., Clevert, D. A., Heimer, M. M., & Cyran, C. C. (2025). Contrast-enhanced ultrasound with VEGFR2-targeted microbubbles for monitoring combined anti-PD-L1/anti-CTLA-4 immunotherapy effects in a murine melanoma model with immunohistochemical validation. PLOS One. https://doi.org/10.1371/journal.pone.0326675

Vancouver

Herr FL, Antons MJ, Blume LV, Hirner-Eppeneder H, Kloiber-Langhorst S, Cimic A, et al. Contrast-enhanced ultrasound with VEGFR2-targeted microbubbles for monitoring combined anti-PD-L1/anti-CTLA-4 immunotherapy effects in a murine melanoma model with immunohistochemical validation. PLOS One. 2025. doi:10.1371/journal.pone.0326675

BibTeX
@article{Herr2025,
  author = {Herr, Felix L and Antons, Melissa J and Blume, Larissa V and Hirner-Eppeneder, Heidrun and Kloiber-Langhorst, Sandra and Cimic, Amra and Stueckl, Jennifer and Tardy, Isabelle and Burkard, Tanja and Ricke, Jens and Kunz, Wolfgang G and Clevert, Dirk-Andre and Heimer, Maurice M and Cyran, Clemens C},
  title = {Contrast-enhanced ultrasound with VEGFR2-targeted microbubbles for monitoring combined anti-PD-L1/anti-CTLA-4 immunotherapy effects in a murine melanoma model with immunohistochemical validation},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0326675}
}
Kostenlos starten →